Government approves 51 pharma companies for bulk drug manufacturing incentives biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Get latest articles and stories on Business at LatestLY. FY22-23 is the first year of production for the PLI Scheme for pharmaceuticals, the department said, adding that the department has earmarked about Rs 690 crore as Budget outlay in the present fiscal. Business News | PLI Scheme for Pharmaceuticals: Govt Releases Rs 166-cr Incentives in First Batch.
Read more about Govt gives approval to four firms under PLI scheme for bulk drugs on Business Standard. The government has given approval to four waitlisted firms under the Production Linked Incentive (PLI) scheme for domestic manufacturing of bulk drugs, an official statement said on Monday.The Department of Pharmaceuticals had launched the PLI
India Business News: The government has given approval to four waitlisted firms under the production linked incentive (PLI) scheme for domestic manufacturing of bulk drugs
PIL scheme: Govt approves four applications for KSMs/drug intermediaries, APIs
May 31, 2021
Forty six applications with committed investment of ₹5,355.44 crore have been approved so far
The government, on Monday, approved four applications under its production-linked scheme for promotion of the domestic manufacturing of Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
According to a Chemicals and Fertilizers Ministry statement, Solara Active Pharma Science Limited received approval for 1,1 Cyclohexane Diacetic Acid (CDA) under the chemical synthesis-based KSMs/Drug Intermediates segment, and Rajasthan Antibiotics Ltd received nod for Meropenem Other Chemical Synthesis Based KSMs/Drug Intermediates and APIs.
Similarly, Dhatri Lab Private Ltd has received approval for Ritonavir and Vital Laboratories Private Ltd for Levofloxacin under the segment of Other Chemical Synthesis-based KSMs/Drug Intermediates and APIs. These firms were se